VUNO Reports Impressive Q3 Earnings Driven by DeepCARS Growth
- 11 Consecutive Quarters of Revenue Growth; Q3 Revenue Exceeds KRW 10 billion for the First Time
VUNO Inc., a prominent medical AI company, has proudly announced its profitability for the third quarter of 2025. The company recorded consolidated revenue of KRW 10.8 billion, along with an operating profit and net profit of KRW 1.0 billion each.
This marks a remarkable year-on-year revenue increase of approximately 58%, jumping from KRW 6.9 billion in the same quarter last year. Furthermore, it reflects a quarter-on-quarter growth of 17% from the previous quarter's KRW 9.3 billion. VUNO's achievement of 11 consecutive quarters of revenue growth emphasizes its unwavering market presence. Additionally, this quarter's revenue marks a historic milestone, as it is the first time VUNO's quarterly earnings have crossed KRW 10 billion since the company's inception in 2014.
Cumulative revenue over the first three quarters of 2025 stands at KRW 27.6 billion, already surpassing the total for the entire year of 2024, which was KRW 25.9 billion. This remarkable feat has enabled VUNO to achieve its annual growth objectives well ahead of schedule.
The profits for this quarter were primarily fueled by gains in core product lines along with enhanced management efficiency. VUNO Med-DeepCARS (DeepCARS) generated KRW 7.0 billion in revenue during Q3, representing an 18% year-on-year growth and making a crucial contribution to the company’s overall revenue. Strategies such as optimizing the product portfolio, refining operational practices, and effective cost management have also played a significant role in boosting profitability.
Chief Financial Officer Joon Kim stated, "Stable revenue growth from our main products and improved management efficiency have strengthened our financial foundation. These results demonstrate the commercialization potential of our medical AI solutions, and we aim to establish a sustainable profit model while accelerating our global expansion."
DeepCARS stands out as a leading AI solution in the South Korean medical landscape, with capabilities to predict the risk of in-hospital cardiac arrest within a mere 24 hours for patients in general wards. Currently, it operates across around 50,000 hospital beds throughout the country. As part of its international growth, VUNO is gearing up for pilot tests in collaboration with a European entity and hospitals in Germany, following its CE-MDR certification. In the U.S. market, the company is actively pursuing FDA clearance and has showcased its innovative solutions at major critical care conferences. Strategic partnerships with leading U.S. hospital systems are also being established to facilitate a smoother market entry.
About VUNO
Founded in 2014, VUNO has emerged as a forefront player in South Korea’s medical AI sector, recognized for developing the nation’s first AI-powered medical device. The company utilizes cutting-edge AI technology to evaluate a vast array of medical data—ranging from bio signals like ECG and respiratory rates to medical images such as X-rays and CT scans—to forecast critical events and assist healthcare professionals in their decision-making. With a steadfast commitment to patient-centered innovation, VUNO endeavours to make high-quality healthcare accessible around the globe.
About VUNO Med -DeepCARS
VUNO Med-DeepCARS (DeepCARS) is an advanced AI-powered medical device intended to monitor the likelihood of in-hospital cardiac arrest occurring within the next 24 hours. It performs a thorough analysis of essential vital signs—including blood pressure, heart rate, respiratory rate, and body temperature—of patients situated in general wards. As of late 2025, DeepCARS has been integrated into over 50,000 hospital beds across South Korea, including more than 20 tertiary general hospitals, proving itself as a critical component in medical care. In 2023, DeepCARS received Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration (FDA) and is currently navigating the FDA approval process.
Frequently Asked Questions
What are VUNO's recent financial highlights?
In the third quarter of 2025, VUNO reported consolidated revenue of KRW 10.8 billion with an operating profit and net profit of KRW 1.0 billion each.
How has DeepCARS performed in the third quarter?
DeepCARS generated KRW 7.0 billion in Q3 revenue, reflecting an 18% annual growth, and continues to be a crucial pillar of VUNO's financial success.
What innovative strategies does VUNO employ?
VUNO optimizes its product portfolio and integrates streamlined operations and effective cost management to enhance profitability and sustain growth.
What is VUNO's global expansion strategy?
VUNO is pursuing partnerships for pilot testing in Europe and is actively undertaking steps to secure FDA approval in the United States to broaden its market reach.
What is the role of DeepCARS in patient care?
DeepCARS predicts in-hospital cardiac arrest risk for patients and is utilized across approximately 50,000 hospital beds, significantly contributing to patient safety and care.
